|
1
|
Xu Z, Zeng X, Tian D, Xu H, Cai Q, Wang J
and Chen Q: MicroRNA-383 inhibits anchorage-independent growth and
induces cell cycle arrest of glioma cells by targeting CCND1.
Biochem Biophys Res Commun. 453:833–838. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang C, Bao Z, Zhang W and Jiang T:
Progress on molecular biomarkers and classification of malignant
gliomas. Front Med. 7:150–156. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu H, Liu Q, Cai T, Chen YD, Liao F and
Wang ZF: miR-136 modulates glioma cell sensitivity to temozolomide
by targeting astrocyte elevated gene-1. Diagn Pathol. 9:1732014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Low SY, Ho YK, Too HP, Yap CT and Ng WH:
MicroRNA as potential modulators in chemoresistant high-grade
gliomas. J Clin Neurosci. 21:395–400. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al European Organisation for Research and Treatment
of Cancer Brain Tumour and Radiation Oncology Groups; National
Cancer Institute of Canada Clinical Trials Group: Effects of
radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumour and Radiation Oncology Groups; National Cancer
Institute of Canada Clinical Trials Group: Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl J
Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Haapasalo J, Hyartt A, Salmi M, Nordfors
K, Lahtela SL, Kähkönen M, Helén P and Haapasalo H: Diagnosis and
prognosis of gliomas - current prospects of molecular diagnostics.
Duodecim. 130:893–901. 2014.In Finnish.
|
|
9
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ryan BM, Robles AI and Harris CC: Genetic
variation in microRNA networks: The implications for cancer
research. Nat Rev Cancer. 10:389–402. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu C, Liang S, Xiao S, Lin Q, Chen X, Wu
Y and Fu J: MicroRNA-27b inhibits Spry2 expression and promotes
cell invasion in glioma U251 cells. Oncol Lett. 9:1393–1397.
2015.PubMed/NCBI
|
|
14
|
Wu D, Zhou Y, Pan H, Qu P and Zhou J:
MicroRNA-99a inhibits cell proliferation, colony formation ability,
migration and invasion by targeting fibroblast growth factor
receptor 3 in prostate cancer. Mol Med Rep. 11:1469–1475. 2015.
|
|
15
|
Kuhn AR, Schlauch K, Lao R, Halayko AJ,
Gerthoffer WT and Singer CA: MicroRNA expression in human airway
smooth muscle cells: Role of miR-25 in regulation of airway smooth
muscle phenotype. Am J Respir Cell Mol Biol. 42:506–513. 2010.
View Article : Google Scholar :
|
|
16
|
Baek D, Villén J, Shin C, Camargo FD, Gygi
SP and Bartel DP: The impact of microRNAs on protein output.
Nature. 455:64–71. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun YC, Wang J, Guo CC, Sai K, Wang J,
Chen FR, Yang QY, Chen YS, Wang J, To TS, et al: miR-181b
sensitizes glioma cells to teniposide by targeting MDM2. BMC
Cancer. 14:6112014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou Y, Wu D, Tao J, Qu P, Zhou Z and Hou
J: MicroRNA-133 inhibits cell proliferation, migration and invasion
by targeting epidermal growth factor receptor and its downstream
effector proteins in bladder cancer. Scand J Urol. 47:423–432.
2013. View Article : Google Scholar
|
|
21
|
Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, Yin
C and Zhang W: MicroRNA-133 inhibits cell proliferation, migration
and invasion in prostate cancer cells by targeting the epidermal
growth factor receptor. Oncol Rep. 27:1967–1975. 2012.PubMed/NCBI
|
|
22
|
Kawakami K, Enokida H, Chiyomaru T,
Tatarano S, Yoshino H, Kagara I, Gotanda T, Tachiwada T, Nishiyama
K, Nohata N, et al: The functional significance of miR-1 and
miR-133a in renal cell carcinoma. Eur J Cancer. 48:827–836. 2012.
View Article : Google Scholar
|
|
23
|
Szafranska AE, Davison TS, John J, Cannon
T, Sipos B, Maghnouj A, Labourier E and Hahn SA: MicroRNA
expression alterations are linked to tumorigenesis and
non-neoplastic processes in pancreatic ductal adenocarcinoma.
Oncogene. 26:4442–4452. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chiyomaru T, Enokida H, Tatarano S,
Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N
and Nakagawa M: miR-145 and miR-133a function as tumour suppressors
and directly regulate FSCN1 expression in bladder cancer. Br J
Cancer. 102:883–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ruebel K, Leontovich AA, Stilling GA,
Zhang S, Righi A, Jin L and Lloyd RV: MicroRNA expression in ileal
carcinoid tumors: Downregulation of microRNA-133a with tumor
progression. Mod Pathol. 23:367–375. 2010. View Article : Google Scholar :
|
|
26
|
Rao PK, Missiaglia E, Shields L, Hyde G,
Yuan B, Shepherd CJ, Shipley J and Lodish HF: Distinct roles for
miR-1 and miR-133a in the proliferation and differentiation of
rhabdomyosarcoma cells. FASEB J. 24:3427–3437. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Du L, Borkowski R, Zhao Z, Ma X, Yu X, Xie
XJ and Pertsemlidis A: A high-throughput screen identifies miRNA
inhibitors regulating lung cancer cell survival and response to
paclitaxel. RNA Biol. 10:1700–1713. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen X, Bo L, Zhao X and Chen Q:
MicroRNA-133a inhibits cell proliferation, colony formation
ability, migration and invasion by targeting matrix
metallopeptidase 9 in hepatocellular carcinoma. Mol Med Rep.
11:3900–3907. 2015.PubMed/NCBI
|
|
29
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumors of the central nervous system. Acta
Neuropathologica. 114:97–109. 2007. View Article : Google Scholar
|
|
30
|
Tao J, Wu D, Li P, Xu B, Lu Q and Zhang W:
MicroRNA-18a, a member of the oncogenic miR-17-92 cluster, targets
Dicer and suppresses cell proliferation in bladder cancer T24
cells. Mol Med Rep. 5:167–172. 2012.
|
|
31
|
Nelson KM and Weiss GJ: MicroRNAs and
cancer: Past, present, and potential future. Mol Cancer Ther.
7:3655–3660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kano M, Seki N, Kikkawa N, Fujimura L,
Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and
Matsubara H: miR-145, miR-133a and miR-133b: Tumor-suppressive
miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J
Cancer. 127:2804–2814. 2010. View Article : Google Scholar
|
|
33
|
Rao PK, Kumar RM, Farkhondeh M,
Baskerville S and Lodish HF: Myogenic factors that regulate
expression of muscle-specific microRNAs. Proc Natl Acad Sci USA.
103:8721–8726. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bostjancic E, Zidar N, Stajer D and Glavac
D: MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated
in human myocardial infarction. Cardiology. 115:163–169. 2010.
View Article : Google Scholar
|
|
35
|
Moriya Y, Nohata N, Kinoshita T, Mutallip
M, Okamoto T, Yoshida S, Suzuki M, Yoshino I and Seki N: Tumor
suppressive microRNA-133a regulates novel molecular networks in
lung squamous cell carcinoma. J Hum Genet. 57:38–45. 2012.
View Article : Google Scholar
|
|
36
|
Nohata N, Hanazawa T, Kikkawa N, Sakurai
D, Sasaki K, Chiyomaru T, Kawakami K, Yoshino H, Enokida H,
Nakagawa M, et al: Identification of novel molecular targets
regulated by tumor suppressive miR-1/miR-133a in maxillary sinus
squamous cell carcinoma. Int J Oncol. 39:1099–1107. 2011.PubMed/NCBI
|
|
37
|
Wong TS, Liu XB, Chung-Wai Ho A, Po-Wing
Yuen A, Wai-Man Ng R and Ignace Wei W: Identification of pyruvate
kinase type M2 as potential oncoprotein in squamous cell carcinoma
of tongue through microRNA profiling. Int J Cancer. 123:251–257.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kinoshita T, Nohata N, Fuse M, Hanazawa T,
Kikkawa N, Fujimura L, Watanabe-Takano H, Yamada Y, Yoshino H,
Enokida H, et al: Tumor suppressive microRNA-133a regulates novel
targets: Moesin contributes to cancer cell proliferation and
invasion in head and neck squamous cell carcinoma. Biochem Biophys
Res Commun. 418:378–383. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Qiu T, Zhou X, Wang J, Du Y, Xu J, Huang
Z, Zhu W, Shu Y and Liu P: miR-145, miR-133a and miR-133b inhibit
proliferation, migration, invasion and cell cycle progression via
targeting transcription factor Sp1 in gastric cancer. FEBS Lett.
588:1168–1177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qin Y, Dang X, Li W and Ma Q: miR-133a
functions as a tumor suppressor and directly targets FSCN1 in
pancreatic cancer. Oncol Res. 21:353–363. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Guo J, Xia B, Meng F and Lou G: miR-133a
suppresses ovarian cancer cell proliferation by directly targeting
insulin-like growth factor 1 receptor. Tumour Biol. 35:1557–1564.
2014. View Article : Google Scholar
|
|
42
|
Uchida Y, Chiyomaru T, Enokida H, Kawakami
K, Tatarano S, Kawahara K, Nishiyama K, Seki N and Nakagawa M:
miR-133a induces apoptosis through direct regulation of GSTP1 in
bladder cancer cell lines. Urol Oncol. 31:115–123. 2013. View Article : Google Scholar
|
|
43
|
Chiyomaru T, Enokida H, Kawakami K,
Tatarano S, Uchida Y, Kawahara K, Nishiyama K, Seki N and Nakagawa
M: Functional role of LASP1 in cell viability and its regulation by
microRNAs in bladder cancer. Urol Oncol. 30:434–443. 2012.
View Article : Google Scholar
|
|
44
|
Li AY, Yang Q and Yang K: miR-133a
mediates the hypoxia-induced apoptosis by inhibiting TAGLN2
expression in cardiac myocytes. Mol Cell Biochem. 400:173–181.
2015. View Article : Google Scholar
|
|
45
|
Feng X, Miao G, Han Y and Xu Y: CARMA3 is
overexpressed in human glioma and promotes cell invasion through
MMP9 regulation in A172 cell line. Tumour Biol. 35:149–154. 2014.
View Article : Google Scholar
|
|
46
|
Yan Y, Liang H, Li T, Li M, Li R, Qin X
and Li S: The MMP-1, MMP-2, and MMP-9 gene polymorphisms and
susceptibility to bladder cancer: A meta-analysis. Tumour Biol.
35:3047–3052. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Roy R, Yang J and Moses MA: Matrix
metalloproteinases as novel biomarkers and potential therapeutic
targets in human cancer. J Clin Oncol. 27:5287–5297. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang X, Lv S, Liu Y, Li D, Shi R, Tang Z,
Fan J and Xu Z: The clinical utility of matrix metalloproteinase 9
in evaluating pathological grade and prognosis of glioma patients:
A meta-analysis. Mol Neurobiol. 52:38–44. 2015. View Article : Google Scholar
|
|
49
|
Stetler-Stevenson WG: Type IV collagenases
in tumor invasion and metastasis. Cancer Metastasis Rev. 9:289–303.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Choi JY, Jang YS, Min SY and Song JY:
Overexpression of MMP-9 and HIF-1α in breast cancer cells under
hypoxic conditions. J Breast Cancer. 14:88–95. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Aalinkeel R, Nair BB, Reynolds JL, Sykes
DE, Mahajan SD, Chadha KC and Schwartz SA: Overexpression of MMP-9
contributes to invasiveness of prostate cancer cell line LNCaP.
Immunol Invest. 40:447–464. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kumar B, Koul S, Petersen J, Khandrika L,
Hwa JS, Meacham RB, Wilson S and Koul HK: p38 mitogen-activated
protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer
by modulation of MMP-2 and MMP-9 activity. Cancer Res. 70:832–841.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhao J, Li G, Zhao Z, Wang J, Gao G and He
S: Matrix metalloproteinase-9 expression is increased in astrocytic
glioma and associated with prognosis of patients. Jpn J Clin Oncol.
42:1060–1065. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Du R, Lu KV, Petritsch C, Liu P, Ganss R,
Passegué E, Song H, Vandenberg S, Johnson RS, Werb Z and Bergers G:
HIF1alpha induces the recruitment of bone marrow-derived vascular
modulatory cells to regulate tumor angiogenesis and invasion.
Cancer Cell. 13:206–220. 2008. View Article : Google Scholar : PubMed/NCBI
|
